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Raw  Data  of  Primordial  Follicle  Number, 
Recent corpora lutea and Fmr1 mRNA Levels 




















Fmr1 mRNA Levels 
Animal Id  Genotype  Remarks (PCR)  Body Weight  Ct Value  Fold Changes 
09-17087-04 Wt  Wt  13.2  23,27  1 
09-17087-03 Wt  Wt  12.2  22,91  1 
09-17652-05 Wt  Wt  11.8  22,25  1 
09-17507-02 Wt  Wt  12.6  23,49  1 
09-17507-04 Wt  Wt  14.4  22,02  1 
09-17654-05 Wt  Wt  10.2  22,92  1 
09-17654-03 Wt  Wt  11.9  24,53  1 
09-17909-05 homrep  PA137/199  11.9  20,87  3.75 
09-17909-04 homrep  PA134/173  12.2  21,01  3.3 
09-17909-06 homrep  PA134/173  11.6  20,26  5.68 
09-17995-04 homrep  PA140  12.1  21,47  2.59 





















Primordial Follicle number 
Group P6 
Descriptives
  Group  Statistic
Primordial Follicle Number  Homrep   Mean  4019.0909
95% Confidence Interval for 
Mean 
Lower Bound  3028.6507
Upper Bound  5009.5312
  5% Trimmed Mean  3939.7121
Median  4007.0000
Variance 2173525.491




Interquartile Range  1614.00
Skewness  1.116
Kurtosis  1.865
Hetrep    Mean  3371.7273
95% Confidence Interval for 
Mean 
Lower Bound  2535.8763
Upper Bound  4207.5782
  5% Trimmed Mean  3422.4192
Median  3511.0000
Variance 1547981.818




Interquartile Range  2636.00
Skewness  -.545




WT    Mean  2835.6364
95% Confidence Interval for 
Mean 
Lower Bound  2031.6399
Upper Bound  3639.6328
  5% Trimmed Mean  2847.4848
Median  2776.0000
Variance 1432242.255












  Statistic df
Primordial Follicle Number  Homrep .240 11
Hetrep  .227 11
WT  .152 11









  Sig. Statistic df Sig.
Primordial Follicle Number  Homrep .077 .907 11  .222
Hetrep  .119 .877 11  .094
WT  .200
* .924 11  .352
a. Lilliefors Significance Correction 






  Group  N Mean  Std. Deviation  Std. Error Mean
Primordial Follicle Number  Homrep 11 4019.0909 1474.28813  444.51460




    Levene's Test for Equality of 
Variances 
t-test for Equality 
of Means 
       
    F Sig. t
Primordial Follicle Number  Equal variances assumed  .000  .986 2.067
Equal variances not assumed     2.067
Independent Samples Test
    t-test for Equality of Means 
     
    df Sig. (2-tailed)  Mean Difference
Primordial Follicle Number  Equal variances assumed  20 .052  1183.45455
Equal variances not assumed 19.189 .052  1183.45455
Independent Samples Test
    t-test for Equality of Means 
   
 
95% Confidence Interval of the 
Difference
    Std. Error 
Difference Lower  Upper 
Primordial Follicle Number  Equal variances assumed  572.53565  -10.83389 2377.74298







  Group  Statistic
Primordial Follicle Number  Homrep   Mean  1232.8333
95% Confidence Interval for 
Mean 
Lower Bound  1027.2367
Upper Bound  1438.4300
  5% Trimmed Mean  1230.6481
Median  1192.0000
Variance 38381.367




Interquartile Range  345.75
Skewness  .384
Kurtosis  -1.078
WT    Mean  757.7143
95% Confidence Interval for 
Mean 
Lower Bound  408.2181
Upper Bound  1107.2104
  5% Trimmed Mean  748.4048
Median  847.0000
Variance 142805.905
















  Statistic df
Primordial Follicle Number  Homrep .204 6
WT  .195 7









  Sig. Statistic df Sig.
Primordial Follicle Number  Homrep .200
* .960 6 .817
WT  .200
* .924 7 .504
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
T-Test 
Independent Samples Test
    Levene's Test for Equality of 
Variances 
t-test for Equality 
of Means 
       
    F Sig. t
Primordial Follicle Number  Equal variances assumed  1.574  .236 2.766
Equal variances not assumed     2.902
Independent Samples Test
    t-test for Equality of Means 
     
    df Sig. (2-tailed)  Mean Difference
Primordial Follicle Number  Equal variances assumed  11 .018  475.11905
Equal variances not assumed 9.260 .017  475.11905




    t-test for Equality of Means 
   
 
95% Confidence Interval of the 
Difference
    Std. Error 
Difference Lower  Upper 
Primordial Follicle Number  Equal variances assumed  171.78493  97.02296 853.21514
Equal variances not assumed 163.70015  106.38310 843.85500
Group ~20wk 
Descriptives
  Group  Statistic
Primordial Follicle Number  Homrep   Mean  718.2000
95% Confidence Interval for 
Mean 
Lower Bound  448.1754
Upper Bound  988.2246
  5% Trimmed Mean  719.1111
Median  710.5000
Variance 142482.400




Interquartile Range  808.25
Skewness  .056
Kurtosis  -1.717
WT    Mean  574.0000
95% Confidence Interval for 
Mean 
Lower Bound  469.1845
Upper Bound  678.8155
  5% Trimmed Mean  573.6667
Median  594.0000
Variance 9975.600















  Statistic df
Primordial Follicle Number  Homrep .171 10
WT  .194 6









  Sig. Statistic df Sig.
Primordial Follicle Number  Homrep .200
* .908 10  .269
WT  .200
* .927 6 .558
a. Lilliefors Significance Correction 




    Levene's Test for Equality of 
Variances 
t-test for Equality 
of Means 
       
    F Sig. t
Primordial Follicle Number  Equal variances assumed  11.118  .005 .905








  Group  N Mean Rank  Sum of Ranks 
Primordial Follicle Number  Homrep 10 9.10 91.00 
WT  6 7.50 45.00 





  Primordial 
Follicle Number
Mann-Whitney U  24.000
Wilcoxon W  45.000
Z -.651
Asymp. Sig. (2-tailed)  .515
Exact Sig. [2*(1-tailed Sig.)]  .562
a
a. Not corrected for ties. 




  Group  Statistic
Primordial Follicle Number  Homrep   Mean  318.8571
95% Confidence Interval for 
Mean 
Lower Bound  215.0250
Upper Bound  422.6893










Interquartile Range  232.00
Skewness  .885
Kurtosis  -.746
WT    Mean  161.7778
95% Confidence Interval for 
Mean 
Lower Bound  96.5884
Upper Bound  226.9672
  5% Trimmed Mean  162.1975
Median  156.0000
Variance 7192.444















  Statistic df
Primordial Follicle Number  Homrep .316 7
WT  .101 9












  Sig. Statistic df Sig.
Primordial Follicle Number  Homrep .034 .856 7 .139
WT  .200
* .983 9 .978
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
T-Test 
Independent Samples Test
    Levene's Test for Equality of 
Variances 
t-test for Equality 
of Means 
       
    F Sig. t
Primordial Follicle Number  Equal variances assumed  .678  .424 3.196
Equal variances not assumed     3.081
Independent Samples Test
    t-test for Equality of Means 
     
    df Sig. (2-tailed)  Mean Difference
Primordial Follicle Number  Equal variances assumed  14 .006  157.07937
Equal variances not assumed 10.898 .011  157.07937
Independent Samples Test
    t-test for Equality of Means 
   
 
95% Confidence Interval of the 
Difference
    Std. Error 
Difference Lower  Upper 
Primordial Follicle Number  Equal variances assumed  49.14995  51.66321 262.49552
Equal variances not assumed 50.98823  44.72642 269.43231




~20wk * Recent Corpus Luteum Crosstabulation
      Recent Corpus Luteum   
      Yes No  Total 
~20wk  Homrep Count  6 4 10
Expected Count  7.5 2.5  10.0
% within ~20wk  60.0% 40.0%  100.0%
% within Recent Corpus 
Luteum 
50.0% 100.0%  62.5%
% of Total  37.5% 25.0%  62.5%
Wt  Count  6 0 6
Expected Count  4.5 1.5  6.0
% within ~20wk  100.0% .0% 100.0%
% within Recent Corpus 
Luteum 
50.0% .0% 37.5%
% of Total  37.5% .0% 37.5%
  Total  Count  12 4 16
Expected Count  12.0 4.0  16.0
% within ~20wk  75.0% 25.0%  100.0%
% within Recent Corpus 
Luteum 
100.0% 100.0%  100.0%










Pearson Chi-Square  3.200
a 1 .074    
Continuity Correction
b 1.422 1 .233    
Likelihood Ratio  4.534 1 .033    
Fisher's Exact Test        .234  .115
Linear-by-Linear Association  3.000 1 .083    
N of Valid Cases  16        




~20wk * Recent Corpus Luteum Crosstabulation
      Recent Corpus Luteum   
      Yes No  Total 
~20wk  Homrep Count  6 4 10
Expected Count  7.5 2.5  10.0
% within ~20wk  60.0% 40.0%  100.0%
% within Recent Corpus 
Luteum 
50.0% 100.0%  62.5%
% of Total  37.5% 25.0%  62.5%
Wt  Count  6 0 6
Expected Count  4.5 1.5  6.0
% within ~20wk  100.0% .0% 100.0%
% within Recent Corpus 
Luteum 
50.0% .0% 37.5%
% of Total  37.5% .0% 37.5%
  Total  Count  12 4 16
Expected Count  12.0 4.0  16.0
% within ~20wk  75.0% 25.0%  100.0%
% within Recent Corpus 
Luteum 
100.0% 100.0%  100.0%
b. Computed only for a 2x2 table 
 
Presence of Recent Corpus Luteum from ~40wk 
~40wk * Recent Corpus Luteum Crosstabulation
      Recent Corpus Luteum   
      Yes No  Total 
~40wk  Homrep Count  0 7 7
Expected Count  3.1 3.9  7.0
% within ~40wk  .0% 100.0%  100.0%
% within Recent Corpus 
Luteum 




% of Total  .0% 43.8%  43.8%
Wt  Count  7 2 9
Expected Count  3.9 5.1  9.0
% within ~40wk  77.8% 22.2%  100.0%
% within Recent Corpus 
Luteum 
100.0% 22.2%  56.3%
% of Total  43.8% 12.5%  56.3%
  Total  Count  7 9 16
Expected Count  7.0 9.0  16.0
% within ~40wk  43.8% 56.3%  100.0%
% within Recent Corpus 
Luteum 
100.0% 100.0%  100.0%












Pearson Chi-Square  9.679
a 1 .002    
Continuity Correction
b 6.777 1 .009    
Likelihood Ratio  12.395 1 .000    
Fisher's Exact Test        .003  .003
Linear-by-Linear Association  9.074 1 .003    
N of Valid Cases  16        
a. 3 cells (75.0%) have expected count less than 5. The minimum expected count is 3.06. 
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